BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax is a first-in-class, highly selective and orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), which is an apoptotic protein that can be overexpressed in some CLL patients.